Primary endpoint based on patient reported outcomes from study expected in October 2023With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described
Jaguar Completes Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea Primary endpoint based on patient reported. | May 9, 2023
FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Jaguar Health (JAGX) Granted FDA Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.